Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chilly vests reveal hidden fat secrets that could fight obesity

NCT ID NCT06424132

Knowledge-focused Sponsor: Rockefeller University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times

Summary

This study investigates why brown fat, which burns calories to generate heat, stops working when it's warm. Researchers will use cold vests on 8 healthy and obese adults to see how genes and proteins change. The goal is to find new targets for treating obesity and related metabolic problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cold vest exposure
What this could lead to
If successful, this could identify new targets for treating obesity and metabolic disorders by reactivating brown fat.
What could go wrong
This is a very small, early-stage study with only 8 participants, so findings may not apply broadly. It focuses on biomarkers, not a direct treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 years old and 35 2. Lean group: BMI is between 18.5 and 24.9. HgA1c \<5.7% 3. Obese group: BMI is \>30, HgA1c \<5.7% 4. Obese group with Type II diabetes: BMI is \>30, HgA1c is \>6.5% If on oral medication for diabetes management, HgA1c may be \< 6.5% The following medications are also acceptable: statins, aspirin, angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB). Exclusion Criteria: 1. Diabetes type I (self-report) 2. Diagnosis of thyroid disease (including goiter, hyperthyroidism, hypothyroidism, thyroiditis)(self-report) 3. Diagnosis with cancer including skin cancer (self-report) 4. Diagnosis or evidence of Raynaud's Syndrome or systemic sclerosis (self-report) 5. A recent diagnosis of Coronavirus Disease 2019 (COVID-19) (last 2 weeks) or hospitalized at the time of diagnosis with COVID-19 6. Any vaccine administration within two weeks preceding the study procedure 7. Currently pregnant 8. Currently taking any prescribed medication other than oral contraceptives. Treatments for weight loss or any other supplements that may alter weight or metabolism are not acceptable. Vitamins are acceptable. 9. Has consumed nicotine (smoking, inhaling, ingesting) within the last 6 months 10. Has used illicit drugs within the last 6 months (marijuana users are eligible unless consumed in the last 30 days). 11. Any medical, psychological, or social condition that, in opinion of principle investigators, would jeopardize the health or well-being of the participant during the study procedure or the integrity of the data 12. Diabetes Type II that is managed by insulin. 13. Steroid use in the last 30 days to the exclusions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cold exposure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic disease Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cold exposure Metabolic disease Obesity

Contacts and locations

Locations

  • Rockefeller University

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.